NeOnc Technologies Holdings, Inc. (NTHI) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning, everyone. Welcome to the Neon Technologies Investment Conference, Paul, to discuss top-line results from the Phase 2845 of our NEO100-01 clinical style, the recurrent IDH1-Newton's high-grade glioma. Joining me on the call today, we have Amir Heshmatpour, our Chief Executive Officer and Executive Chairman, We also have Dr. Thomas Chen to my right, who's our founder and chief medical officer and chief scientific officer. We also have Dr. Josh Neman, who's our chief clinical officer. My name is Keithly Garnett. I serve as the chief financial officer. Today, we're also joined by one of our board members, Mr. Mayor Jim Delshad, and other board members are participating through the webcast. Before we begin, I would like to remind everyone that during this call, we will make forward-looking statements within the meeting of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. These statements can be identified by words such as may, will, should, intend, expect, plan, anticipate, believe, estimate, predict, potential, continue, evaluating, and other similar terms. These statements reflect our current expectations and subject to known and unknown risk and circumstances and uncertainties that can cause actual results to differ materially. Among other things, results of preclinical studies and early clinical trials may not be predictive of results in future clinical trials. Announced or published data may change as more patient data becomes available and are subject to audits and verification procedures that can result in material changes to the final data. Our product candidates are in clinical stages of development, are not approved for commercial sale and might never receive regulatory approval or become commercially viable. ...